• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

UK Age RCT Final Results: Breast Cancer Screening Beginning at Age 40 with 23 Years Follow-Up

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • The best age range for mammographic breast cancer screening is still disputed
  • Duffy et al. (Lancet Oncology, 2020) provides the final report from the UK Age study that sought to estimate the effect of mammographic screening at ages 40 to 48 years on breast cancer mortality

METHODS:

  • Randomized controlled trial
  • Participants
    • Women 39 to 41 years
  • Interventions
    • Yearly mammographic screening
      • From the year of inclusion in the trial up to and including the calendar year that they reached age 48 years
    • Standard care
      • No screening until the invitation to their first National Health Service Breast Screening Programme (NHSBSP) screen at approximately age 50 years
  • Study design
    • Women were randomized 1:2 (intervention: control)
    • Intervention group: Recruited by postal invitation
    • Control group: Unaware of the study
  • To study the timing of the mortality effect, the authors analyzed the results in different follow-up periods
    • Analysis was on an intention-to-treat basis
  • Primary outcome
    • Mortality from breast cancers diagnosed during the intervention period | Deaths from all breast cancers diagnosed after randomization, but before first NHSBSP invitation
  • Secondary outcomes
    • Mortality from all breast cancers diagnosed after randomization until the data cutoff date
    • All-cause mortality
    • Incidence of breast cancer

RESULTS:

  • Yearly mammogram screening group: 53,883 women | Control group: 106,953 women
  • Median follow-up: 22.8 years (IQR 21.8 to 24.0)
  • Breast cancer mortality was reduced at 10 years of follow-up (P=0.029)
    • Breast cancer deaths in yearly screening group: 83
    • Breast cancer deaths in control group: 219
    • Relative rate (RR) 0.75 (95% CI, 0.58 to 0.97)
  • Breast cancer mortality was not significantly reduced after 10 years (P=0.86)
    • Breast cancer deaths in yearly screening group: 126
    • Breast cancer deaths in control group: 255
    • RR 0.98 (95% CI, 0.79 to 1.22)
  • Overall, breast cancer mortality was not significantly reduced by the end of follow up (P=0.13)
    • Breast cancer deaths in yearly screening group: 209 deaths
    • Breast cancer deaths in control group: 474 deaths
    • RR 0.88 (95% CI, 0.74 to 1.03)
  • There was no significant difference in all-cause mortality
    • RR 1.01 (95% CI, 0·96 to 1.05; p=0·66)

CONCLUSION:

  • Breast cancer mortality was reduced by approximately 25% in women who were invited to a program of yearly mammography screening between age 40 and 48
    • There was no benefit seen after 10 years of follow-up
  • There was no reduction in all cause mortality

Learn More – Primary Sources:

Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

More from the WHI: Are Breast Cancers That Develop Between Mammograms Associated with Worse Survival Outcomes?
How Effective Is Mammography in Reducing the Number of Advanced Breast Cancer Diagnoses?
Can Ultrasonography in Addition to Mammography Improve Breast Cancer Screening Effectiveness?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site